Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Ontario Clinical Oncology Group (OCOG)
National Cancer Institute (NCI)
University of Göttingen
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Mahidol University